Post-approval Studies Aim To Resolve Lingering Safety Fears For Diabetes Drug Farxiga
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency finally clears AstraZeneca/Bristol Myers-Squibb’s SGLT-2 inhibitor Farxiga (dapagliflozin), but with post-marketing strings attached.